CONTEXT: PTH may be an effective treatment option for hypoparathyroidism, but long-term data are not available. OBJECTIVE: We studied the effect of 4 yr of PTH(1-84) treatment in hypoparathyroidism. DESIGN: Twenty-seven subjects were treated with PTH(1-84) for 4 yr, with prospective monitoring of calcium and vitamin D requirements, serum and urinary calcium, serum phosphorus, bone turnover markers, and bone mineral density (BMD). RESULTS: Treatment with PTH(1-84) reduced supplemental calcium requirements by 37% (P = 0.006) and 1,25-dihydroxyvitamin D requirements by 45% (P = 0.008). Seven subjects (26%) were able to stop 1,25-dihydroxyvitamin D completely. Serum calcium concentration remained stable, and urinary calcium and phosphorus excretion fell. Lumbar spine BMD increased by 5.5 ± 9% at 4 yr (P < 0.0001). Femoral neck and total hip BMD remained stable. At 4 yr, distal radius BMD was not different from baseline. Bone turnover markers increased significantly, reaching a 3-fold peak from baseline values at 6-12 months (P < 0.05 for all), subsequently declining to steady-state levels at 30 months. Hypercalcemia was uncommon (11 episodes in eight subjects over 4 yr; 1.9% of all values), with most episodes occurring within the first 6 months and resolving with adjustment of supplemental calcium and vitamin D. CONCLUSIONS: PTH(1-84) treatment of hypoparathyroidism for up to 4 yr maintains the serum calcium concentration, while significantly reducing supplemental calcium and 1,25-dihydroxyvitamin D requirements. Lumbar spine BMD increases without significant changes at other sites. These data provide support for the safety and efficacy of PTH(1-84) therapy in hypoparathyroidism for up to 4 yr.
CONTEXT: PTH may be an effective treatment option for hypoparathyroidism, but long-term data are not available. OBJECTIVE: We studied the effect of 4 yr of PTH(1-84) treatment in hypoparathyroidism. DESIGN: Twenty-seven subjects were treated with PTH(1-84) for 4 yr, with prospective monitoring of calcium and vitamin D requirements, serum and urinary calcium, serum phosphorus, bone turnover markers, and bone mineral density (BMD). RESULTS: Treatment with PTH(1-84) reduced supplemental calcium requirements by 37% (P = 0.006) and 1,25-dihydroxyvitamin D requirements by 45% (P = 0.008). Seven subjects (26%) were able to stop 1,25-dihydroxyvitamin D completely. Serum calcium concentration remained stable, and urinary calcium and phosphorus excretion fell. Lumbar spine BMD increased by 5.5 ± 9% at 4 yr (P < 0.0001). Femoral neck and total hip BMD remained stable. At 4 yr, distal radius BMD was not different from baseline. Bone turnover markers increased significantly, reaching a 3-fold peak from baseline values at 6-12 months (P < 0.05 for all), subsequently declining to steady-state levels at 30 months. Hypercalcemia was uncommon (11 episodes in eight subjects over 4 yr; 1.9% of all values), with most episodes occurring within the first 6 months and resolving with adjustment of supplemental calcium and vitamin D. CONCLUSIONS:PTH(1-84) treatment of hypoparathyroidism for up to 4 yr maintains the serum calcium concentration, while significantly reducing supplemental calcium and 1,25-dihydroxyvitamin D requirements. Lumbar spine BMD increases without significant changes at other sites. These data provide support for the safety and efficacy of PTH(1-84) therapy in hypoparathyroidism for up to 4 yr.
Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245
Authors: Karen K Winer; Chia Wen Ko; James C Reynolds; Karen Dowdy; Meg Keil; Donna Peterson; Lynn H Gerber; Charles McGarvey; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: D W Dempster; R Müller; H Zhou; T Kohler; E Shane; M Parisien; S J Silverberg; J P Bilezikian Journal: Bone Date: 2007-04-11 Impact factor: 4.398
Authors: S J Silverberg; E Shane; L de la Cruz; D W Dempster; F Feldman; D Seldin; T P Jacobs; E S Siris; M Cafferty; M V Parisien Journal: J Bone Miner Res Date: 1989-06 Impact factor: 6.741
Authors: Cristiana Cipriani; Alice Abraham; Barbara C Silva; Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Chengchen Zhang; Didier Hans; Shonni J Silverberg; John P Bilezikian Journal: Endocrine Date: 2016-10-18 Impact factor: 3.633
Authors: Abhishek Chandra; Tiao Lin; Mary Beth Tribble; Ji Zhu; Allison R Altman; Wei-Ju Tseng; Yejia Zhang; Sunday O Akintoye; Keith Cengel; X Sherry Liu; Ling Qin Journal: Bone Date: 2014-07-01 Impact factor: 4.398
Authors: Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Dinaz Irani; Amanda Tulley; James Sliney; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2013-04-17 Impact factor: 5.958